{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:09:51Z","timestamp":1789513791651,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T00:00:00Z","timestamp":1304985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10147-011-0246-y","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T06:43:04Z","timestamp":1304923384000},"page":"671-678","source":"Crossref","is-referenced-by-count":23,"title":["Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-\u03b1 on pancreatic cancer cells"],"prefix":"10.1007","volume":"16","author":[{"given":"Shuichi","family":"Iwahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Morine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Imura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ikemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,10]]},"reference":[{"key":"246_CR1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605\u20131617","journal-title":"N Engl J Med"},{"key":"246_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"246_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32\u201342","journal-title":"Nat Rev Genet"},{"key":"246_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38\u201351","journal-title":"Nat Rev Cancer"},{"key":"246_CR5","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420\u20135432","journal-title":"Oncogene"},{"key":"246_CR6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1006\/bbrc.2001.5639","volume":"287","author":"SK Patra","year":"2001","unstructured":"Patra SK, Patra A, Dahiya R (2001) Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287:705\u2013713","journal-title":"Biochem Biophys Res Commun"},{"key":"246_CR7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","volume":"5","author":"P Zhu","year":"2004","unstructured":"Zhu P, Martin E, Mengwasser J et al (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:455\u2013463","journal-title":"Cancer Cell"},{"key":"246_CR8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/35895","volume":"391","author":"RJ Lin","year":"1998","unstructured":"Lin RJ, Nagy L, Inoue S et al (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811\u2013814","journal-title":"Nature"},{"key":"246_CR9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MPA.0b013e31815f2c2a","volume":"36","author":"K Miyake","year":"2008","unstructured":"Miyake K, Yoshizumi T, Imura S et al (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36:e1\u2013e9","journal-title":"Pancreas"},{"key":"246_CR10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2005","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2005) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"246_CR11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","volume":"90","author":"RP Warrell Jr","year":"1998","unstructured":"Warrell RP Jr, He LZ, Richon V et al (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621\u20131625","journal-title":"J Natl Cancer Inst"},{"key":"246_CR12","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969\u20136978","journal-title":"EMBO J"},{"key":"246_CR13","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","volume":"66","author":"Q Xia","year":"2006","unstructured":"Xia Q, Sung J, Chowdhury W et al (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237\u20137244","journal-title":"Cancer Res"},{"key":"246_CR14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/jc.2004-1355","volume":"90","author":"MG Catalano","year":"2005","unstructured":"Catalano MG, Fortunati N, Pugliese M et al (2005) Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90:1383\u20131389","journal-title":"J Clin Endocrinol Metab"},{"key":"246_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0166-3542(94)90058-2","volume":"24","author":"S Baron","year":"1994","unstructured":"Baron S, Dianzani F (1994) The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res 24:97\u2013110","journal-title":"Antiviral Res"},{"key":"246_CR16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/mrd.1080390216","volume":"39","author":"PJ Hertzog","year":"1994","unstructured":"Hertzog PJ, Hwang SY, Kola I (1994) Role of interferons in the regulation of cell proliferation, differentiation and development. Mol Reprod Dev 39:226\u2013232","journal-title":"Mol Reprod Dev"},{"key":"246_CR17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","volume":"91","author":"JU Gutterman","year":"1994","unstructured":"Gutterman JU (1994) Cytokine therapeutics: lessons from interferon-\u03b1. Proc Natl Acad Sci USA 91:1198\u20131205","journal-title":"Proc Natl Acad Sci USA"},{"key":"246_CR18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jnci\/80.5.306","volume":"80","author":"SE Krown","year":"1988","unstructured":"Krown SE (1988) Interferons in malignancy: biological products or biological response modifiers? J Natl Cancer Inst (Bethesda) 80:306\u2013309","journal-title":"J Natl Cancer Inst (Bethesda)"},{"key":"246_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00280-006-0250-5","volume":"59","author":"K Miyake","year":"2007","unstructured":"Miyake K, Tsuchida K, Sugino H et al (2007) Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha. Cancer Chemother Pharmacol 59:113\u2013126","journal-title":"Cancer Chemother Pharmacol"},{"key":"246_CR20","first-page":"93","volume":"3","author":"DE Baker","year":"2003","unstructured":"Baker DE (2003) Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord 3:93\u2013109","journal-title":"Rev Gastroenterol Disord"},{"key":"246_CR21","first-page":"2125","volume":"37","author":"T Yamada","year":"2010","unstructured":"Yamada T, Furukawa K, Yokoi K et al (2010) Effects of irinotecan and 5-FU combination therapy in gastric cancer\u2014is combination therapy synergic (in Japanese)? Gan To Kagaku Ryoho 37:2125\u20132129","journal-title":"Gan To Kagaku Ryoho"},{"key":"246_CR22","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.emboj.7601025","volume":"25","author":"YG Yoo","year":"2006","unstructured":"Yoo YG, Kong G, Lee MO (2006) Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 25:1231\u20131241","journal-title":"EMBO J"},{"key":"246_CR23","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, O\u2019Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923\u20133931","journal-title":"J Clin Oncol"},{"key":"246_CR24","first-page":"971","volume":"2","author":"L Fuino","year":"2003","unstructured":"Fuino L, Bali P, Wittmann S et al (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971\u2013984","journal-title":"Mol Cancer Ther"},{"key":"246_CR25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.surg.2005.06.016","volume":"138","author":"BK Rundall","year":"2005","unstructured":"Rundall BK, Denlinger CE, Jones DR (2005) Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138:360\u2013367","journal-title":"Surgery"},{"key":"246_CR26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","volume":"75","author":"WS El-Deiry","year":"1993","unstructured":"El-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817\u2013825","journal-title":"Cell"},{"key":"246_CR27","first-page":"1169","volume":"54","author":"WS El-Deiry","year":"1994","unstructured":"El-Deiry WS, Harper JW, O\u2019Connor PM et al (1994) WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169\u20131174","journal-title":"Cancer Res"},{"key":"246_CR28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90039-X","volume":"82","author":"C Deng","year":"1995","unstructured":"Deng C, Zhang P, Harper JW et al (1995) Mice lacking p21CIP1\/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675\u2013684","journal-title":"Cell"},{"key":"246_CR29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI117806","volume":"95","author":"J Schwaller","year":"1995","unstructured":"Schwaller J, Koeffler HP, Niklaus G et al (1995) Posttranscriptional stabilization underlies p53-independent induction of p21WAF1\/CIP1\/SDI1 in differentiating human leukemic cells. J Clin Invest 95:973\u2013979","journal-title":"J Clin Invest"},{"key":"246_CR30","first-page":"884","volume":"147","author":"JA DiGiuseppe","year":"1995","unstructured":"DiGiuseppe JA, Redston MS, Yeo CJ et al (1995) p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 147:884\u2013888","journal-title":"Am J Pathol"},{"key":"246_CR31","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/sj.onc.1203963","volume":"19","author":"L Huang","year":"2000","unstructured":"Huang L, Sowa Y, Sakai T et al (2000) Activation of the p21WAF1\/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19:5712\u20135719","journal-title":"Oncogene"},{"key":"246_CR32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","volume":"85","author":"CM Das","year":"2007","unstructured":"Das CM, Aguilera D, Vasquez H et al (2007) Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85:159\u2013170","journal-title":"J Neurooncol"},{"key":"246_CR33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/mc.10145","volume":"38","author":"M Donadelli","year":"2003","unstructured":"Donadelli M, Costanzo C, Faggioli L et al (2003) Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 38:59\u201369","journal-title":"Mol Carcinog"},{"key":"246_CR34","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","volume":"97","author":"VM Richon","year":"2000","unstructured":"Richon VM, Sandhoff TW, Rifkind RA et al (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014\u201310019","journal-title":"Proc Natl Acad Sci USA"},{"key":"246_CR35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1078-0432.CCR-06-0914","volume":"13","author":"B Nichole","year":"2007","unstructured":"Nichole B, Nohea A, Jason G et al (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13:18\u201326","journal-title":"Clin Cancer Res"},{"key":"246_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-004-0549-1","volume":"54","author":"P Tagliaferri","year":"2005","unstructured":"Tagliaferri P, Caraglia M, Budillon A et al (2005) New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother 54:1\u201310","journal-title":"Cancer Immunol Immunother"},{"key":"246_CR37","doi-asserted-by":"crossref","first-page":"22958","DOI":"10.1016\/S0021-9258(17)31603-4","volume":"269","author":"Y Toh","year":"1994","unstructured":"Toh Y, Pencil SD, Nicolson GL (1994) A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 269:22958\u201322963","journal-title":"J Biol Chem"},{"key":"246_CR38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0092-8674(03)00274-5","volume":"113","author":"R Kumar","year":"2003","unstructured":"Kumar R (2003) Another tie that binds the MTA family to breast cancer. Cell 113:142\u2013143","journal-title":"Cell"},{"key":"246_CR39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbaexp.2003.10.010","volume":"1677","author":"NJ Bowen","year":"2004","unstructured":"Bowen NJ, Fujita N, Kajita M et al (2004) Mi-2\/NuRD: multiple complexes for many purposes. Biochim Biophys Acta 1677:52\u201357","journal-title":"Biochim Biophys Acta"},{"key":"246_CR40","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1016\/S0002-9610(03)00051-5","volume":"185","author":"VJ Picozzi","year":"2003","unstructured":"Picozzi VJ, Kozarek RA, Traverso LW (2003) Interferon based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185:4767\u20134780","journal-title":"Am J Surg"},{"key":"246_CR41","first-page":"1858","volume":"9","author":"CC Solorzano","year":"2003","unstructured":"Solorzano CC, Hwang R, Baker CH et al (2003) Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 9:1858\u20131867","journal-title":"Clin Cancer Res"},{"key":"246_CR42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1023\/A:1016214030069","volume":"20","author":"F Perez-Zincer","year":"2002","unstructured":"Perez-Zincer F, Olencki T, Budd GT et al (2002) A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma. Invest New Drugs 20:305\u2013310","journal-title":"Invest New Drugs"},{"key":"246_CR43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00001813-200210000-00001","volume":"13","author":"S Fuxius","year":"2002","unstructured":"Fuxius S, Mross K, Mansouri K et al (2002) Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer. Anticancer Drugs 13:899\u2013905","journal-title":"Anticancer Drugs"},{"key":"246_CR44","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00280-007-0568-7","volume":"61","author":"RJ Amato","year":"2008","unstructured":"Amato RJ, Khan M (2008) A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. Cancer Chemother Pharmacol 61:1069\u20131073","journal-title":"Cancer Chemother Pharmacol"},{"key":"246_CR45","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.0022-202X.2004.23433.x","volume":"123","author":"C Krepler","year":"2004","unstructured":"Krepler C, Certa U, Wacheck V et al (2004) Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol 123:664\u2013669","journal-title":"J Invest Dermatol"},{"key":"246_CR46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","volume":"25","author":"RA Blaheta","year":"2005","unstructured":"Blaheta RA, Michaelis M, Driever PH et al (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25:383\u2013397","journal-title":"Med Res Rev"},{"key":"246_CR47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/hmg\/9.2.227","volume":"9","author":"A Faiella","year":"2000","unstructured":"Faiella A, Wernig M, Consalez GG et al (2000) A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet 9:227\u2013236","journal-title":"Hum Mol Genet"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0246-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-011-0246-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0246-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T22:56:31Z","timestamp":1637621791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-011-0246-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,10]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1007\/s10147-011-0246-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,10]]}}}